With Veeva (VEEV) having announced that long-term strategic partner Merck (MRK) is committing to migrate to Vault CRM, Barclays notes that six of the top 20 pharma companies have committed to migrating to Vault, compared to two of the top 20 that are making an eventual move to Salesforce (CRM) Life Sciences Cloud. The firm has an Overweight rating and $300 price target on Veeva shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Oppenheimer sees Merck agreement as strong endorsement for Veeva’s Vault CRM
- Veeva Systems’ Strong Market Position and Growth Potential: A Buy Rating by Dylan Becker
- Veeva announces Merck committed to Veeva Vault CRM
- Veeva Systems: Strategic Positioning and Growth Potential with Crossix Integration
- Veeva Systems Inc. Advances Infant Nutrition with Glycoprotein Formula Study